Thyroid Radioiodine Uptake Research Articles

Iodine prophylaxis intensification

Poland, a country with mild/moderate iodine deficiency introduced an obligatory iodination salt system in 1996. To compare the results of radioiodine (131I) uptake after 5 h and 24 h with the activity of radioiodine used in the treatment of hyperthyroid patients with Graves' disease in the years 1995 and 2003. The marker of iodine content in the diet was urinary iodine excretion. 1000 randomly chosen patients (average age: 46 +/- 12 years) were included in the study. Every patient had routinely estimated radioiodine uptake after 5 h and 24 h and the activity of 131I was calculated using scintigraphy and ultrasonography of the thyroid gland. Urinary iodine excretion in samples from year 1995 and 2003 was also determined in some patients and healthy volunteers. The iodine load in the diet increased from 66 microg (average) in the year 1995 to 115 microg in the year 2003. Thyroid radioiodine uptake was 40% lower in comparison with the results from 1995. The average activity of 131I given in the year 2003 (10 mCi) was about 40% higher than in the year 1995 (7 mCi). There was significant negative correlation between higher iodine content in the diet and lower values of radioiodine uptake, which led to the application of the higher activity of 131I during treatment.

Rapid regulation of thyroid sodium–iodide symporter activity by thyrotrophin and iodine

Transport of iodide into thyrocytes, a fundamental step in thyroid hormone biosynthesis, depends on the presence of the sodium-iodide symporter (NIS). The importance of the NIS for diagnosis and treatment of diseases has raised several questions about its physiological control. The goal of this study was to evaluate the influence of thyroid iodine content on NIS regulation by thyrotrophin (TSH) in vivo. We showed that 15-min thyroid radioiodine uptake can be a reliable measurement of NIS activity in vivo. The effect of TSH on the NIS was evaluated in rats treated with 1-methyl-2-mercaptoimidazole (MMI; hypothyroid with high serum TSH concentrations) for 21 days, and after 1 (R1d), 2 (R2d), or 5 (R5d) days of withdrawal of MMI. NIS activity was significantly greater in both MMI and R1d rats. In R2d and R5d groups, thyroid iodide uptake returned to normal values, despite continuing high serum TSH, possibly as a result of the re-establishment of iodine organification after withdrawal of MMI. Excess iodine (0.05% NaI for 6 days) promoted a significant reduction in thyroid radioiodide uptake, an effect that was blocked by concomitant administration of MMI, confirming previous findings that iodine organification is essential for the iodide transport blockade seen during iodine overload. Therefore, our data show that modulation of the thyroid NIS by TSH depends primarily on thyroid iodine content and, further, that the regulation of NIS activity is rapid.

Reduced radioiodine uptake at increased iodine intake and 131I-induced release of “cold” iodine stored in the thyroid

Summary Aim: The extent of urinary iodine excretion (UIE) provides information about iodine supply and release. In the present study we investigated correlations between UIE and radioiodine uptake (RIU) as well as effects of radioiodine therapy on UIE in patients with autonomous goitre. Patients, methods: In 197 consecutive patients with thyroid autonomy, UIE was measured twice during radioiodine test (RITe) and correlated with RIU. In 98 of these patients, thyroglobulin and thyroid volume (V) were determined prior to therapy. Individual changes in urinary iodine excretion (ΔUIE) and TG (ΔTG) could be investigated four weeks (4W) and six months (6M) after radioiodine therapy. Additionally, ΔV was determined 6M after therapy. ΔUIE, ΔTG and ΔV were correlated with target dose and target volume. Results: Patients with higher iodine excretion exhibited significantly lower thyroidal radioiodine uptake values. Twofold increased UIE prior to therapy decreased radioiodine uptake by 25%. Compared with pretherapeutic values, UIE and TG were significantly increased four weeks after radioiodine therapy (p <0.001). Median values of both parameters were found to be doubled. The product of target dose and target volume was not only correlated with a decrease of thyroid volume 6M after therapy, but also with an increase of UIE and TG in the early phase after therapy. Conclusions: It was confirmed that UIE during RITe is a measure for iodine intake and can be used to investigate the competition between stable iodine and radioiodine. The increase of UIE and TG four weeks after therapeutic administration of radioiodine can be explained by disintegrated thyroid follicles. The therapy-induced iodine release may be one important cause for the development of hyperthyroidism in some patients during the first weeks after radioiodine therapy. It may contribute to the known decrease of radioiodine uptake after preapplications of 131I in various thyroid diseases.

Modulation of thyroidal radioiodine uptake by theophylline

Diagnostic and therapeutic use of radioiodine in the management of thyroid disorders depends on the ability of thyroid cells to concentrate radioiodine, a process regulated by thyrotropin and dependent on the intracellular increase in cAMP. We tested the ability of theophylline, a drug known to increase intracellular cAMP via inhibition of phosphodiesterase, to modulate the thyroidal radioiodine uptake in FRTL-5 cells, in mice and in humans. In FRTL-5 cells, theophylline increased the uptake of radioactive iodine and intracellular cAMP only at low concentrations (1 μM). In mice, theophylline increased slightly the radioiodine uptake, although this increase varied from 1.5- to 6.6-fold. In humans, theophylline decreased slightly the radioiodine uptake, a decrease that became more pronounced with time after radioiodine administration. These studies suggest that theophylline modulates the radioiodine uptake in a dose-dependent fashion, although the modulation is mild and probably not applicable to the clinical setting.

Iodination and radiolabeling of α-allocryptopine with iodine-125

A procedure for labeling of α-allocryptopine with 125I is reported in this article. α-allocryptopine is first iodinated with largely excessive iodine monochloride, and then radiolabeled by isotopic exchange with Na125I in a dichloromethane–water two-phase system. The radiochemical purity and yield of the labeled product are typically as high as 94% and 72%, respectively. Further chromatographic purification gives a highly pure product (radiochemical purity >99%). The distribution of 125I-labeled α-allocryptopine in mice at 2h after injection shows that the uptake of radioiodine in thyroid is negligibly low.

Theophylline increases the uptake of radioiodine by mouse thyroid.

Diagnostic and therapeutic use of radioiodine in the management of thyroid disorders depends on the ability of thyroid cells to concentrate radioiodine, a process that is regulated by the intracellular increase in cAMP. We hypothesized that theophylline, a drug known to increase intracellular cAMP via inhibition of phosphodiesterase, could increase thyroidal radioiodine uptake. We tested this effect in vivo, using C57BL/6j mice, and in vitro, using Fisher rat thyroid (FRTL-5) cells. One mouse received 2.5mg theophylline i.p., whereas a control mouse received only saline. Twenty-hours after theophylline, mice were injected with 10 µCi Na125I in 0.1 mL saline through the tail vein. Mean thyroidal 125I activity was 3.3-fold higher in theophylline-treated mice than in their respective controls. Radioiodine uptake and intracellular cAMP production of FRTL-5 cells were increased by a relatively low concentration of theophylline (1 µM). Intracellular cAMP increased up to 30 min and then declined in response to 1 µM theophylline. Sera from theophylline-treated mice stimulated 125I uptake and intracellular cAMP production by FRTL-5 cells. These findings show that theophylline can enhance radioiodine uptake by thyrocytes in vivo and in vitro. The in vitro effects of theophylline on both radioiodine uptake and cAMP production in a dose-dependent manner are consistent with an action mediated by phosphodiesterase inhibition.

Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis

Amiodarone-induced thyrotoxicosis (AMT) is a life-threatening condition, the appropriate management of which is achieved by identifying its different subtypes. Type 1 AIT develops in patients with underlying thyroid abnormalities and is believed to be due to increased thyroid hormone synthesis and release; Type 2 AIT occurs in patients with a normal thyroid gland and is an amiodarone-induced destructive process of the thyroid. Management differs in the two forms of AIT, since Type 1 usually responds to combined thionamides and potassium perchlorate therapy, while Type 2 is generally responsive to glucocorticoids. Mixed forms, characterized by coexistence of excess thyroid hormone synthesis and destructive phenomena, may require a combination of the two therapeutic regimens. In this cross-sectional prospective study, 55 consecutive untreated patients, whose AIT was subtyped according to clinical and biochemical criteria, were evaluated to assess the specificity of color flow doppler sonography (CFDS) and thyroidal radioiodine uptake (RAIU) in the differential diagnosis of AIT. Sixteen patients (6 men, 10 women, age 66+/-13 yr), who had diffuse or nodular goiter with or without circulating thyroid autoantibodies, were classified as Type 1 AIT; 39 patients (27 men, 12 women, age 65+/-13 yr) with apparently normal thyroids were classified as Type 2 AIT. All Type 1 patients had normal or increased thyroidal vascularity on CFDS, while Type 2 AIT patients had absent vascularity (p<0.0001). Thirteen Type 1 AIT patients had inappropriately normal or elevated thyroidal 3-h and 24-h RAIU values (range 6-37% and 10-58%, respectively), in spite of elevated values of urinary iodine excretion; the remaining 3 patients (two with nodular goiter, one with a thyroid adenoma) had low 3-h and 24-h RAIU values (range 1.1-3.0% and 0.9-4.0%, respectively). The latter patients, who were unresponsive to the combination of methimazole and potassium perchlorate, became euthyroid after the addition of glucocorticoids. Thirty-eight Type 2 AIT patients had low 3-h and 24-h RAIU values (range 0.4-3.7% and 0.2-3.0%, respectively), but one had inappropriately normal 3-h and 24-h RAIU values (6% and 13%, respectively). In conclusion, CFDS can accurately distinguish between Type 1 and Type 2 AIT, and in general the CFDS pattern is concordant with the thyroid RAIU. However, in 4 out of 55 patients (7%) the thyroid RAIU was discrepant, probably reflecting the coexistence of Type 1 and Type 2 AIT. Thus, assessment of both CFDS and RAIU may provide a more accurate subtyping of AIT and help in selecting the appropriate therapy. Finally, in long standing iodine sufficient areas, such as the United States, where the thyroid RAIU is consistently low irrespective of the etiology of the AIT, CFDS offers a rapid and available method to differentiate between Type 1 and Type 2 AIT.

Health effects assessment for environmental perchlorate contamination: the dose response for inhibition of thyroidal radioiodine uptake in humans.

Application of a sensitive new detection method has revealed widespread perchlorate contamination of groundwater in the southwestern United States, typically at 0.005-0.020 mg/L (5-20 ppb). Perchlorate is a competitive inhibitor of the process by which iodide is actively transported from the bloodstream into the thyroid. This inhibitory action of perchlorate is the basis of its pharmaceutical use (in the treatment of hyperthyroidism) as well as its potential toxicity. To establish the dose response in humans for perchlorate inhibition of thyroidal iodide uptake and any short-term effects on thyroid hormones, we gave perchlorate in drinking water at 0.007, 0.02, 0.1, or 0.5 mg/kg-day to 37 male and female volunteers for 14 days. In 24 subjects we performed 8- and 24-hr measurements of thyroidal (123)I uptake (RAIU) before exposure, on exposure days 2 (E2) and 14 (E14), and 15 days postexposure (P15). In another 13 subjects we omitted both E2 studies and the 8-hr P15 study. We observed a strong correlation between the 8- and 24-hr RAIU over all dose groups and measurement days. We found no difference between E2 and E14 in the inhibition of RAIU produced by a given perchlorate dose. We also found no sex difference. On both E2 and E14, the dose response was a negative linear function of the logarithm of dose. Based on the dose response for inhibition of the 8- and 24-hr RAIU on E14 in all subjects, we derived estimates of the true no-effect level: 5.2 and 6.4 micro g/kg-day, respectively. Given default body weight and exposure assumptions, these doses would be ingested by an adult if the drinking-water supply contained perchlorate at concentrations of approximately 180 and 220 micro g/L (ppb), respectively. On P15, RAIU was not significantly different from baseline. In 24 subjects we measured serum levels of thyroxine (total and free), triiodothyronine, and thyrotropin in blood sampled 16 times throughout the study. Only the 0.5 mg/kg-day dose group showed any effect on serum hormones: a slight downward trend in thyrotropin levels in morning blood draws during perchlorate exposure, with recovery by P15.

The effects of amiodarone on the thyroid.

Amiodarone is a benzofuranic-derivative iodine-rich drug widely used for the treatment of tachyarrhythmias and, to a lesser extent, of ischemic heart disease. It often causes changes in thyroid function tests (typically an increase in serum T(4) and rT(3), and a decrease in serum T(3), concentrations), mainly related to the inhibition of 5'-deiodinase activity, resulting in a decrease in the generation of T(3) from T(4) and a decrease in the clearance of rT(3). In 14-18% of amiodarone-treated patients, there is overt thyroid dysfunction, either amiodarone-induced thyrotoxicosis (AIT) or amiodarone-induced hypothyroidism (AIH). Both AIT and AIH may develop either in apparently normal thyroid glands or in glands with preexisting, clinically silent abnormalities. Preexisting Hashimoto's thyroiditis is a definite risk factor for the occurrence of AIH. The pathogenesis of iodine-induced AIH is related to a failure to escape from the acute Wolff-Chaikoff effect due to defects in thyroid hormonogenesis, and, in patients with positive thyroid autoantibody tests, to concomitant Hashimoto's thyroiditis. AIT is primarily related to excess iodine-induced thyroid hormone synthesis in an abnormal thyroid gland (type I AIT) or to amiodarone-related destructive thyroiditis (type II AIT), but mixed forms frequently exist. Treatment of AIH consists of L-T(4) replacement while continuing amiodarone therapy; alternatively, if feasible, amiodarone can be discontinued, especially in the absence of thyroid abnormalities, and the natural course toward euthyroidism can be accelerated by a short course of potassium perchlorate treatment. In type I AIT the main medical treatment consists of the simultaneous administration of thionamides and potassium perchlorate, while in type II AIT, glucocorticoids are the most useful therapeutic option. Mixed forms are best treated with a combination of thionamides, potassium perchlorate, and glucocorticoids. Radioiodine therapy is usually not feasible due to the low thyroidal radioiodine uptake, while thyroidectomy can be performed in cases resistant to medical therapy, with a slightly increased surgical risk.

Early Thyrotoxic Thyroiditis After Radiotherapy for Tonsillar Carcinoma

Thyroiditis with hyperthyroidism is a recognized early complication of intrathyroidal irridiation by orally ingested radiolabeled iodine I 131, but has seldom been described following external delivery of radiotherapy to the thyroid bed. We treated a man who was initially seen with a clinical picture suggestive of hyperthyroidism after receiving a course of radiotherapy for tonsillar carcinoma. Laboratory studies and thyroidal radioiodine uptake confirmed the diagnosis of thyrotoxic thyroiditis, having onset within 2 weeks of completion of the course of radiotherapy. The literature concerning thyroiditis and thyroid function following external beam radiotherapy is reviewed. Because several of the clinical features of thyrotoxic thyroiditis may resemble those resulting from the cancer under treatment or complications of its therapy, we recommend evaluation of thyroid function at the conclusion of the course of radiotherapy and 2 weeks thereafter to exclude this self-limited and treatable cause of weight loss.

Autoradiographic thyroid evaluation in short-term experimental diabetes mellitus.

Previous studies have shown that in vitro thyroid peroxidase (TPO) iodide oxidation activity is decreased and thyroid T4-5'-deiodinase activity is increased 15 days after induction of experimental diabetes mellitus (DM). In the present study we used thyroid histoautoradiography, an indirect assay of in vivo TPO activity, to determine the possible parallelism between the in vitro and in vivo changes induced by experimental DM. DM was induced in male Wistar rats (about 250 g body weight) by a single i.p. streptozotocin injection (45 mg/kg), while control (C) animals received a single injection of the vehicle. Seven and 30 days after diabetes induction, each diabetic and control animal was given i.p. a tracer dose of 125I (2 microCi), 2.5 h before thyroid excision. The glands were counted, weighted, fixed in Bouin's solution, embedded in paraffin and cut. The sections were stained with HE and exposed to NTB-2 emulsion (Kodak). The autohistograms were developed and the quantitative distribution of silver grains was evaluated with a computerized image analyzer system. Thyroid radioiodine uptake was significantly decreased only after 30 days of DM (C: 0.38 +/- 0.05 vs DM: 0.20 +/- 0.04%/mg thyroid, P < 0.05) while in vivo TPO activity was significantly decreased 7 and 30 days after DM induction (C: 5.3 and 4.5 grains/100 micron 2 vs DM: 2.9 and 1.6 grains/100 micron 2, respectively, P < 0.05). These data suggest that insulin deficiency first reduces in vivo TPO activity during short-term experimental diabetes mellitus.

Studies on rat thyroid after oral administration of mancozeb: morphological and biochemical evaluations.

Mancozeb, an ethylenebisdithiocarbamate (EBDC), has been studied for its effects on rat thyroid. Single oral administration of mancozeb at different concentrations (9600, 12,000, 15,000 and 18,750 mg kg(-1) body wt) has derived the oral LD50 value as 15,000 mg kg(-1) body wt. in male rats. Mancozeb at repeated oral doses of 500, 1000 and 1500 mg kg(-1) day(-1) for periods of 30, 90, 180 and 360 days has produced dose-dependent signs of toxicity and death of animals. The fungicide caused a significant increase in thyroid/body weight ratio and histopathological changes. Reduced levels of thyroid radioiodine ([125]I) uptake, serum protein-bound iodine (PB[125]I), thyroxine (T4) and reduced activity of thyroid peroxidase (TPO) have also been observed after exposure to mancozeb. Thus, mancozeb has been shown to produce marked structural and functional changes in thyroid of rats.

Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models: application in pharmacokinetics.

This article proposes three stochastic algorithms to optimize a Bayesian design criterion for Bayesian estimation of the parameters of nonlinear regression models; this criterion is the information expected from an experiment. The first algorithm is based on a stochastic version of the simplex with an adaptive sampling procedure. The others are stochastic approximation algorithms: the Kiefer-Wolfowitz and the pseudogradient algorithms. We first present the information criterion and the optimization algorithms. The efficiency of each algorithm for optimizing this Bayesian design criterion is then assessed by a simulation study for a nonlinear model assuming a discrete prior distribution. An application for designing an experiment to estimate the kinetics of radioiodine thyroid uptake is then proposed.

Update on the thyroid sodium iodide symporter: a novel thyroid antigen emerging on the horizon.

The ability to transport and concentrate iodide, a fundamental property of normally functioning thyroid epithelial cells, represents a key step in the production of the iodine-containing thyroid hormones. Iodide uptake across the basolateral membrane of thyroid follicular cells is made possible by the Na ˛ /I π symporter (NIS), an active co-transport mechanism that is driven by an inwardly directed Na ˛ gradient. In addition to providing a mechanism for several diagnostically useful tests such as the thyroidal radioiodine uptake test and the perchlorate discharge test, NIS-mediated active I π accumulation by thyroid tissue is a crucial requirement for the success of radioactive iodine therapy. As highlighted earlier (1), cloning of the rat NIS from an FRTL-5 cell-derived cDNA library by Carrasco‘s group has revealed an open reading frame of 1854 nucleotides that encodes a 618 amino acid intrinsic membrane protein with 12 putative membrane-spanning domains. This discovery has set the stage for Smanik et al. (2), who subsequently cloned the human homologue of NIS from a human thyroid cDNA library. An open reading frame (nucleotides 348‐2276) of human NIS (hNIS) encodes a protein of 643 amino acids that shares 84% amino acid identity with recombinant NIS (rNIS) and has a predicted molecular mass of 68·7 kDa. Assignment of the 12 transmembrane domains in hNIS has been based on the proposed transmembrane domains of the rNIS, in which the two protein sequences are highly conserved. Transient transfection of COS-7 cells with the hNIS cDNA clone resulted in perchlorate-sensitive iodide uptake, confirming expression of functionally intact hNIS. Using reverse transcriptase-polymerase chain reaction, the authors detected hNIS expression at variable levels in papillary thyroid carcinoma tissues, but not in any of the thyroid carcinoma cell lines that lack iodide uptake activity, suggesting that loss of iodide-concentrating activity in thyroid carcinomas may be due to a loss of hNIS expression. Shortly after cloning of hNIS, Kosugi et al. (3) succeeded in establishing stable expression of recombinant rNIS in a Chinese hamster ovary (CHO) cell line. Subsequent analysis of its basic biochemical and electrophysiological properties, including time course, Na ˛ -dependency, kinetics and competitive inhibition by perchlorate and thiocynate, revealed characteristics

Color flow Doppler sonography in thyrotoxicosis factitia.

Color flow doppler sonography (CFDS) is a powerful technique which displays tissue blood flow and vascularity. Hyperthyroidism due to Graves' disease is characterized by variable degrees of increased blood flow at CFDS. The purpose of this study was to evaluate CFDS patterns in five women with thyrotoxicosis factitia, a condition due to surreptitious ingestion of excess thyroid hormone. Diagnosis was supported by the finding of elevated free thyroxine (FT4), ranging 24.2-67.6 pmol/L (normal values: 8.3-20.5), elevated free triiodothyronine (FT3), ranging 9.9-26.7 pmol/L (normal values: 3.8-8.4), undetectable thyrotropin (TSH), absent anti-thyroid antibodies, undetectable serum thyroglobulin (Tg) concentrations, very low/suppressed thyroidal radioiodine uptake and normal/low urinary iodine excretion. Moreover, all patients admitted thyroid hormone pills intake. All patients had normal thyroid volume and echogenicity at conventional sonography (mean estimated volume, 9.4 ml, range, 6-11 ml), and absent hypervascularity or minimal intrathyroidal vascular spots at CFDS. The peak systolic velocity (PSV) was at the lower limit of normal values (mean, 4 cm/sec, range 3-5 cm/sec). Twenty-six women with untreated Graves' disease had an increase in the mean PSV, (mean 12.9 cm/sec, range 8-20, p < 0.001) and diffuse hypervascularity. CFDS pattern in 24 normal women residing in the same area did not differ from that found in patients with thyrotoxicosis factitia. Thus, due to the nonthyroidal origin of excess thyroid hormone, CFDS showed absent hypervascularity and normal PSV in spite of a thyrotoxic status. These findings well correlate with the etiology of thyrotoxicosis factitia and may represent an additional, useful tool to confirm the diagnosis. For its easiness, rapidity (10 min) and noninvasive features, CFDS can be considered a first line test during office examination when thyrotoxicosis factitia is suspected.

A variant of adenomatous goiter with characteristic histology and possible hereditary thyroglobulin abnormality.

A variant type of adenomatous goiter was identified in 24 of 2160 patients with adenomatous goiter who underwent thyroidectomy. The characteristics of the thyroid gland in these 24 patients included large goiter, small follicles, scant colloid, and columnar follicular cells containing yellow-green granules on hematoxylin-eosin staining. The thyroid gland was slightly orange-red, and electron microscopic examination showed abundant lysosomes with colloid droplets. When comparing the features of this group with those of 24 patients with common adenomatous goiter, the incidence of familial predisposition to thyroid diseases in the former group was higher. The age at the time of detection of goiter was lower, i.e. 17 +/- 15 vs. 44 +/- 17 yr (P < 0.001, variant type vs. common type), the serum total T4 concentrations were lower (84 +/- 21 vs. 103 +/- 18 nmol/L; P < 0.01), and the serum TSH concentrations were higher (2.4 +/- 2.1 vs. 1.0 +/- 0.9 mU/L; P < 0.01). Thyroid radioiodine uptake was remarkably increased (49 +/- 22 vs. 16 +/- 9%; P < 0.001), and lower levels of serum thyroglobulin were noted (33 +/- 51 vs. 484 +/- 603 micrograms/L; P < 0.01). The thyroglobulin content was low in the thyroid gland studied. The data suggest that the etiology of this variant type of goiter is a hereditary abnormality in thyroglobulin synthesis, and this type of goiter may be distinguished from common adenomatous goiter by the characteristic morphology of the thyroid gland in addition to clinical findings.

Prospective randomized comparison of intravenous versus subcutaneous administration of radioiodine for treatment of hyperthyroidism in cats

Summary One hundred twenty cats with hyperthyroidism were treated with radioiodine (131I); 60 cats were administered radioiodine sc, and 60 cats were administered radioiodine iv. Before treatment, radioactive tracer studies were performed on each cat to determine peak radioactive iodine uptake and effective half-life. These data were used to calculate the dose of radioiodine that would have to be given to each cat to deliver 150 Gy to the thyroid tissue. The 2 groups of cats were similar with regard to age, tracer study results, and radioiodine dose. Mean estimated thyroid mass was larger for cats treated iv, but mean serum thyroxine concentration was higher for cats treated sc. Route of administration did not affect thyroidal uptake of radioiodine. However, radiation exposure of personnel was significantly lower with sc administration than with iv administration, even when iv catheterization was performed Eighty-five percent of cats treated iv and 84% of cats treated sc were euthyroid 4 years after treatment. Six percent of the cats became hypothyroid after treatment. When compared with iv administration, sc administration of radioiodine appeared to be as effective for treatment of hyperthyroidism, safer to personnel, and less stressful to the cats.

Diagnostic usefulness of thyroid ultrasonography in atrophic thyroiditis.

An abnormal thyroid echographic pattern, characterized by a diffuse low thyroid echogenicity associated with a reduced thyroid volume, was found in 53 of 55 (96%) patients with atrophic thyroiditis. In 10 of these patients, the ultrasound examination was diagnostic for thyroid atrophy, whereas the scintiscan had no abnormality. In only two cases was the reverse observed, ie, absent thyroid radioiodine uptake and no evidence of abnormality in the ultrasound examination. Six out of 24 (25%) patients with thyroperoxidase antibody titers < or = 1:1600 and 4 of 31 (13%) patients with titers > or = 1:6400 had a normal thyroid scintiscan in the presence of an abnormal thyroid echographic pattern. Thus, thyroid echography can be considered the first morphological procedure in patients with hypothyroidism due to atrophic thyroiditis, and thyroid scintiscan can be used to confirm the diagnosis when other results are not definitive.

Age‐Related Therapeutic Response to Antithyroid Drug in Patients with Hyperthyroid Graves' Disease

To determine whether there is an age-related difference in the therapeutic response to antithyroid drugs in hyperthyroid Graves' disease. Retrospective analysis of treatment duration and recurrence rate. Two hundred and twenty-two patients who have triiodothyronine-suppressible thyroids within 4 years of methimazole treatment. Serum thyroid hormone levels, serum thyrotropin receptor antibody titer, and thyroidal radioiodine uptake. A longer period of methimazole treatment was needed to normalize serum thyroid hormone levels and to restore normal thyroidal triiodothyronine suppressibility in young than in aged patients. There was an average 10-month lag between normalization of thyrotropin receptor antibody titer and restoration of thyroidal triiodothyronine suppressibility in both young and aged patients. Recurrence after discontinuation of methimazole was more frequent in young than in aged patients. Aged patients with hyperthyroid Graves' disease show a more favorable response to antithyroid drugs than young counterparts.

Demonstrable Photopenic Lesion in Tc-99m Pertechnetate Thyroid Imaging After Recent Contrast Radiographic Procedure

Iodine-contained contrast media of a recent arteriogram can block normal thyroid uptake of Tc-99m pertechnetate or radioiodine, resulting in virtual nonvisualization of the thyroid gland and showing a prominent salivary activity. In Tc-99m pertechnetate thyroid imaging, however, diffuse soft-tissue uptake in the anterior neck surrounding a fluid containing (cystic) lesion may standout as photopenia. The authors present two patients with recent contrast radiographic procedures who underwent Tc-99m pertechnetate imagings that demonstrated photopenic lesions: one was a thyroid cyst and the other confirmed an abscess.